Neuren Pharmaceuticals Limited

NURPF

NURPFNeuren Pharmaceuticals Limited US flag

Other OTC

7.76

USD

+0.45

(+6.14%)

0.63EPS

12.32P/E

991.72MMarket Cap

Jan 29Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

NZNEUE0001S8

Return %

Stock

S&P500

-49.84

25.76

204.27

38.63

345.92

83.81

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Revenue per Share	- -	- -	- -	- -	- -	- -	- -	0.14	- -	- -	- -	0.12	1.83
Basic EPS, GAAP	-0.12	-0.09	-0.18	-0.11	-0.16	-0.13	0.04	0.03	-0.11	-0.09	-0.07	- -	1.24
Free Cash Flow per Basic Share	- -	-0.05	-0.12	-0.08	-0.15	-0.14	- -	- -	- -	- -	- -	- -	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	0.08	-0.02	0.23	0.26	0.26	0.16	0.26	0.33	0.22	0.32	0.41	0.39	1.66
Tangible Book Value per Share	0.15	0.05	0.38	0.24	0.17	0.05	0.18	0.25	0.14	0.23	0.33	0.33	1.61
Basic Weighted Avg Shares	38	59	63	78	84	89	92	99	100	107	118	126	127
Sales/Revenue/Turnover	- -	- -	- -	- -	- -	- -	- -	14	- -	- -	- -	15	232
Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	39.07	- -	- -	- -	-11.04	85.89
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	-5	-5	-11	-8	-13	-12	3	3	-11	-9	-8	- -	157
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	23.43
Profit Margin (%)	- -	- -	- -	- -	- -	- -	- -	22.69	- -	- -	- -	1.26	67.73
Working Capital	6	3	24	19	14	4	15	25	14	24	39	42	204
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	9	6	24	19	14	4	16	25	14	24	39	42	205
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	-66.01	25.79	- -	- -	- -	-3.97	107.46
Return on Capital (%)	- -	- -	- -	- -	- -	- -	17.23	10.81	- -	- -	- -	0.38	120.57
Return on Common Equity (%)	- -	- -	- -	-47.52	-63.22	-65.58	17.23	10.81	-38.97	-32.35	-18.74	0.38	120.57

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	- -	1,493.66%
Net Income, GAAP	8,457.62%	16,937.11%	85,270.11%
Free Cash Flow	- -	23.46%	110.53%
Total Cash Common Dividend	- -	- -	- -
Total Equity	71.73%	98.49%	393.42%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Sector: Healthcare
Industry: Biotechnology
Address: 697 Burke Road Camberwell VIC Australia 3124
IPO Date: Nov 4, 2009
Website: neurenpharma.com
Similar Companies: Sangamo Therapeutics, Inc. (GBY.DE)
PELL Bio-Med Technology Co. Ltd. (6949.TW)
LAVA Therapeutics N.V. (LVTX)
Nuvectis Pharma, Inc. (NVCT)
Zai Lab Limited (9688.HK)
Shandong Sito Bio-technology Co., Ltd. (300583.SZ)
Business: Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.


No results.


No results.

Year	Q1	Q2	Q3	Q4	FY
2021	- -	- -	- -	- -	- -
2022	- -	- -	- -	- -	15
2023	- -	- -	- -	- -	232

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Revenue per Share	- -	- -	- -	- -	- -	- -	- -	0.14	- -	- -	- -	0.12	1.83
Basic EPS, GAAP	-0.12	-0.09	-0.18	-0.11	-0.16	-0.13	0.04	0.03	-0.11	-0.09	-0.07	- -	1.24
Free Cash Flow per Basic Share	- -	-0.05	-0.12	-0.08	-0.15	-0.14	- -	- -	- -	- -	- -	- -	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	0.08	-0.02	0.23	0.26	0.26	0.16	0.26	0.33	0.22	0.32	0.41	0.39	1.66
Tangible Book Value per Share	0.15	0.05	0.38	0.24	0.17	0.05	0.18	0.25	0.14	0.23	0.33	0.33	1.61
Basic Weighted Avg Shares	38	59	63	78	84	89	92	99	100	107	118	126	127
Sales/Revenue/Turnover	- -	- -	- -	- -	- -	- -	- -	14	- -	- -	- -	15	232
Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	39.07	- -	- -	- -	-11.04	85.89
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	-5	-5	-11	-8	-13	-12	3	3	-11	-9	-8	- -	157
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	23.43
Profit Margin (%)	- -	- -	- -	- -	- -	- -	- -	22.69	- -	- -	- -	1.26	67.73
Working Capital	6	3	24	19	14	4	15	25	14	24	39	42	204
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	9	6	24	19	14	4	16	25	14	24	39	42	205
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	-66.01	25.79	- -	- -	- -	-3.97	107.46
Return on Capital (%)	- -	- -	- -	- -	- -	- -	17.23	10.81	- -	- -	- -	0.38	120.57
Return on Common Equity (%)	- -	- -	- -	-47.52	-63.22	-65.58	17.23	10.81	-38.97	-32.35	-18.74	0.38	120.57

Neuren Pharmaceuticals Limited

Growth Rates

(avg. rate of change)

Company Description

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year